HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Abroad (travel likely)RecruitingPHASE3

Conditions

Leukemia, Acute Myeloid (AML)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

the First Affiliated Hospital,College of Medicine,Zhejiang University, Hanzhou, China
Contact: Study coordinator (Jie Jin, Doctor) · jiej0503@163.com · 0571-87236685

Study leads

Jie Jin, MD, PhD
Principal Investigator
First Affiliated Hospital of Zhejiang University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

Leukemia · Acute Myeloid Leukemia in Remission · Myelodysplasia

Abroad (travel likely)Recruiting

Milwaukee, United States

National Longitudinal Cohort of Hematological Diseases

Multiple Myeloma · Acute Myeloid Leukemia · Hemophilia

Abroad (travel likely)Recruiting

Tianjin, China

The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT

AML (Acute Myelogenous Leukemia) · AML

Abroad (travel likely)RecruitingEARLY_PHASE1

Beijing, China

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Acute Myeloid Leukemia (AML)

Abroad (travel likely)RecruitingPHASE3

Vienna, Austria · Wels, Austria